Search Results for: search.php

“Nature has developed, very cleverly, some lessons on how to create the features that we desire in optical design,” said Joseph Shaw, director of the Optical…

A review of data from more than 150 studies from the U.S. and other regions showed that high yields were linked to production systems in which corn plants took…

1,3-Dihydroxyacetone (DHA) is a chemical compound used extensively in the cosmetics industry and with a high prospect of being used in synthesis of new biodegradable polymers if the market price were lower. In this invention, the DHA synthesis from glycerol is carried out photocatalytically under normal conditions using low-cost heterogeneous photocatalysts and easily available oxidizing agents.

Targeted therapy has become a promising therapeutic approach within the last decade due to its reduced toxicity. However, further development of targeted approaches for the specific delivery of therapeutically active substances is required. Especially the targeted delivery of macromolecular charged drug-like molecules, for example antagomirs and siRNA, is limited since these candidates do not cross cell membranes but rather have to be actively provided to the intracellular milieu.

The present invention provides novel aptamers capable of recognizing tumour cells and delivering macromolecular molecules into tumour cells. Aptamers are short single-stranded nucleic acids that recognize specific target structures with high affinity and specificity. Additionally, since aptamers have been shown to possess almost no toxicity and immunogenicity they are promising candidates for biomedical applications.

DNA-methylation (DNAm) of CpG dinucleotides is a key epigenetic process. Upon cell division, the DNAm pattern is maintained on the newly synthesized DNA strand by DNA methyltransferase 1 (DNMT1), whereas DNAm pattern changes are triggered by DNMT3A and DNMT3B that act as de novo methyltransferases.
DNMT3A and DNMT3B play a pivotal role in the epigenetic regulation and development of hematopoietic malignant myeloid disease, such as acute myeloid leukemia (AML) and myelodysplastic syndrome. About 22% of AML patients harbor mutations in DNMT3A, which likely cause the disease. However, little is known about how DNMT3s are epigenetically controlled.
The present invention provides a novel diagnostic and prognostic method for hematopoietic malignant myeloid disease. This method is based on the identification of aberrant hypermethylation at an internal promoter region of DNMT3A, which occurs in about 40% of AML patients.

Unsafe bike paths, traffic jam stress, frightening underpasses – modern city dwellers face a number of stressors. According to experts, sustainable urban…